For research use only. Not for therapeutic Use.
PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC50 values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders[1].
PDE1 enzymes are expressed in the central nervous system (CNS), making this gene family an attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders[1].
| Catalog Number | I020680 |
| CAS Number | 1904611-63-7 |
| Synonyms | 6-bromo-7-(cyclopentylmethyl)-3-(oxan-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8-one |
| Molecular Formula | C16H21BrN4O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H21BrN4O2/c17-13-10-21-14(12-5-7-23-8-6-12)18-19-15(21)16(22)20(13)9-11-3-1-2-4-11/h10-12H,1-9H2 |
| InChIKey | UDLAXUPVISWZSI-UHFFFAOYSA-N |
| SMILES | C1CCC(C1)CN2C(=CN3C(=NN=C3C2=O)C4CCOCC4)Br |
| Reference | [1]. Jan Kehler, et al. Triazolopyrazinones as pde1 inhibitors. WO2016055618A1. |
